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Abstract
Angiotensin II (Ang-II) and vascular endothelial growth factor (VEGF) have an important role in the pathogenesis of
diabetic nephropathy, but the signaling cascade of VEGF regulation in response to Ang-II in podocytes is largely
unknown. In these experiments, we looked at the effect of Ang-II on the production of VEGF, and investigated whether
VEGF production depends on the p38 mitogen activated protein kinase (MAPK) pathway in cultured mouse podocytes.
Incubation of podocytes with Ang-II induced a rapid increase in VEGF mRNA expression and protein synthesis as well
as its transcriptional activity in an Ang-II dose-dependent manner. To further define the role of angiotensin type 1 (AT1)
and type 2 (AT2) receptors involved in Ang-II-mediated VEGF synthesis, the effects of selective AT1 and AT2 receptor
antagonists were evaluated. Prior treatment with losartan significantly inhibited VEGF mRNA and protein synthesis
induced by Ang-II, which suggests that the AT1 receptor is involved in Ang-II-mediated VEGF synthesis. Furthermore,
stimulation of the cells with Ang-II increased both phosphorylation of p38 MAPK and MAP kinase kinase 3/6 (MKK3/6).
Additionally, Ang-II enhanced the DNA binding activity to cAMP response element binding protein (CREB) and
phosphorylation of CREB. In addition, to investigate the role of p38 MAPK in Ang-II-induced VEGF synthesis,
podocytes were pretreated with or without the p38 MAPK inhibitor, SB203580 for 24 h to observe whether
Ang-II-mediated VEGF synthesis was inhibited by blocking p38 MAPK. The addition of SB203580 led to a marked
inhibition of the increased VEGF mRNA and protein production induced by Ang-II in a dose-dependent manner. Taken
together, these results suggest that Ang-II stimulates the synthesis of VEGF in podocytes and the production of VEGF
induced by Ang-II is mediated, in part, through the activation of the p38 MAPK pathway.
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Introduction
Diabetic milieu results in the increased expression of
angiogenic growth factors in numerous tissues as a
response to both hyperglycemia and tissue ischemia
(Duh & Aiello 1999, Ferrara 1999). It is generally
accepted that podocytes are the major site of vascular
endothelial growth factor (VEGF) production, and their
regulation in VEGF expression may play an important
role in diabetic nephropathy (Brown et al. 1992, Kretzler
et al. 1998). Podocytes are unique cells in the glomerulus,
cover the outer part of glomerular basement membrane
and function as the final filtration barrier to protein loss.
There is now increasing data supporting a direct role
for VEGF in the pathogenesis of diabetic nephropathy.
VEGF is up-regulated from the early stage of diabetic
nephropathy (Cooper et al. 1999). In vivo blockade of
VEGF abolished hyperfiltration and suppressed the
urinary albumin excretion rate in diabetic rats (De
Vriese et al. 2001). In addition, VEGF may contribute to
mesangial expansion and phagocytes infiltration (Clauss
et al. 1990, Flyvbjerg et al. 2002). Taken together, these
studies suggest that VEGF plays an important role in the
pathogenesis of diabetic nephropathy.
Angiotensin II (Ang-II) plays an important role in the
development of glomerulosclerosis (Leehey et al. 2000).
There are several reports showing that Ang-II increases
VEGF production in human mesangial cells and in
vascular smooth muscle cells (Williams et al. 1995,
Gruden et al. 1999, Pupilli et al. 1999). However, there is
no report on whether Ang-II induces VEGF production
in podocytes, which are the major source of VEGF
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synthesis in the glomerulus. Additionally, the signaling
cascade of VEGF regulation in response to Ang-II in
podocytes is largely unknown. Many studies have
demonstrated protein kinase C activation in diabetic
glomeruli and mesangial cells cultured under high
glucose conditions (Craven & DeRubertis 1989,
Williams & Schrier 1993, Ziyadeh et al. 1995, Hoshi et al.
2002). Increased p38 mitogen activated protein kinase
(MAPK) activity has been demonstrated in diabetic
glomeruli (Kang et al. 2001), and Ang-II also activated
p38 MAPK leading to the induction of fibronectin
expression and cellular growth in rat mesangial cells
(Reddy et al. 2002).
In this study, we examined the eﬀects of Ang-II on
VEGF mRNA expression and protein production in
cultured mouse podocytes, and evaluated whether
VEGF production depends on the p38 MAPK pathway.
In addition, we examined the relationship between the
p38 MAPK pathway and VEGF synthesis in cultured
mouse podocytes.
Materials and methods
Cell cultures
A thermosensitive, SV40-transfected immortalized
mouse podocyte cell line, a generous gift from Peter
Mundel (Albert Einstein College of Medicine, New
York, NY, USA), was used for this study. Cultivation of
mouse podocytes that were conditionally immortalized
with a temperature-sensitive variant of the SV40 large T
antigen (tsA58) and whose activity can be increased by
-interferon, was performed as described previously
(Mundel et al. 1997). To propagate podocytes, cells were
cultivated at 33 C and treated with 10–50 U/ml mouse
recombinant -interferon (permissive condition), which
increases the expression of the temperature-sensitive
large T antigen and cell proliferation. To induce
diﬀerentiation, podocytes were thermoshifted to 37 C
and deprived of -interferon (non-permissive condition)
for 14 days. Studies were performed using a podocytes
cell line at 20–24 passages. Identification of podocytes
was performed using RT-PCR for podocyte specific
markers such as Wilms’ tumor protein (WT-1).
Diﬀerentiation of podocytes was determined on the basis
of the expression of synaptopodin, which is a
diﬀerentiation marker, using RT-PCR.
Experimental design
Diﬀerentiated podocytes were grown to sub-confluence
in type 1 collagen-coated dishes (Iwaki, Tokyo, Japan) in
growth media containing 10% fetal calf serum (FCS),
100 U/ml penicillin, and 0·1 mg/ml streptomycin in
RPMI 1640 medium, and then cultured for 24 h in a
medium containing 5 mmol/l -glucose and 1% FCS
before being exposed to experimental conditions. In the
Ang-II-stimulated group, diﬀerent concentrations of
Ang-II were added to the culture media at final concen-
trations of 1 nM, 10 nM, and 100 nM. To define the
mechanism of Ang-II-mediated VEGF synthesis, we used
both the Ang-II receptor type 1 antagonist (losartan) and
the Ang-II receptor type 2 antagonist (PD123319). When
the eﬀects of these drugs were tested, these compounds
were added to podocytes one hour before Ang-II treat-
ment. All experimental groups were cultured in triplicate
and harvested at 6, 24 and 72 h for extraction of total
RNA and protein. The results are representative of those
from three independent experiments.
To determine the eﬀect of Ang-II on the p38 MAPK
pathway, sub-confluent podocytes were cultured for 24 h
in medium containing 5 mmol/ -glucose and 1% FCS.
Then, the cells were treated with Ang-II at a final concen-
tration of 100 nM, and harvested after 30 min, 1 h, 6 h
and 24 h. In studies examining the role of the p38 MAPK
pathway on VEGF synthesis, SB203580, which is a p38
MAPK inhibitor, was added to podocytes one hour
before Ang-II treatment at final concentrations of 1 and
10 µM. Cells were harvested at 30 min, 1 h, 6 h, and 24 h
and then total RNA and protein were extracted. To avoid
any confounding eﬀects of serum on VEGF and proteins
in the p38 MAPK pathway experiments, serum-free
media were used. All experimental groups were cultured
in triplicate. The results are representative of those from
three independent experiments.
RT-PCR
Total RNA extraction was performed with a Trizol
reagent and the cDNA was synthesized by a reverse
transcription reaction using an RNA PCR kit (Applied
Biosystems, Roche Inc., Foster City, CA, USA) in a
20 µl mixture containing 1 µg RNA, 50 mM KCl,
10 mM Tris/HCl, 5 mM MgCl2, 1 mM of each dNTPs,
oligo-(dT) primers, 20 units RNAse inhibitor and 50
units Moloney Murine Leukemia Virus (MuLV) reverse
transcriptase. The reaction mixture was incubated for
60 min at 42 C, then heated at 90 C for 7 min in a
thermocycler (GeneAmp PCR system 9600, Perkin
Elmer, Roche Molecular System, Branchburg, NJ,
USA). Next, cDNA was amplified by 2·5 units
AmpliTaq Gold polymerase in a 25 µl reaction volume
containing 10 mmol/l Tris–HCl (pH 8·3), 50 mmol/l
KCl, 1·5 mmol/l MgCl2, 0·2 mmol/l deoxynucleoside
triphosphate, and 30 pmol of each primer. Sequence
specific primers for VEGF, designed according to the
mouse sequence (Gene bank number M95200), were
used for the PCR. The nucleotide sequences of each
primer are as follows: sense 5- CAGGCTGCTGT
AACGATGAA-3 and antisense 5-AATGCTTTCTC
CGCTCTGAA-3. As an internal control, -actin was
also amplified and nucleotide sequences for primers are
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as follows: sense 5-TCATGAGGTAGTCCGTCAGG-3
and antisense 5-TCTAGGCACCAAGGTGTG-3. The
PCR conditions were 40 cycles of denaturation at 95 C
for 45 s, annealing at 58 C for 45 s, and extension at
72 C for 3 min. The number of PCR cycles selected
represents a point before the plateau of amplification
products, as described previously (Cha et al. 2000, Kim
et al. 2000). To confirm the identity of each PCR product,
each of the electrophoresed PCR bands were extracted
with a DNA extraction kit (Qiagen, Valencia, CA, USA)
and sequenced using an ABI automated DNA sequencing
system (ABI Genetic Analyzer 310; PRISM, Branchburg
Park, NJ, USA). The RT-PCR products were separated
on a 2% agarose gel with ethidium bromide staining by
electrophoresis. After scanning at 300 d.p.i., densiometric
analysis was performed for quantification using NIH
(Bethesda, MA, USA) image analysis software (version
1·61). The ratios of the concentration of -actin to those
of VEGF were evaluated.
Transient transfection and luciferase reporter
activity assay
VEGF reporter plasmid containing firefly luciferase
linked to VEGF promotor sequences was a generous
gift from Dr P A D’Amore (Shima et al. 1996). Cells
were plated onto 24-well plates at a density of
1105 cells/well. Following 24 h growth, when cells
were approximately 40 to 50% confluence, cells were
transfected with 1 µg VEGF reporter plasmid and 1 µg
plasmid containing Renilla luciferase driven by TK
promotor using Superfect, as recommended by the
manufacturer (Qiagen) for 24 h. Then, media containing
the transfection reagent were replaced with complete
media without serum, and cells were treated with or
without diﬀerent concentrations of angiotensin II at final
concentrations of 1 nM, 10 nM and 100 nM. After 24 h,
luciferase activity was determined using the dual
luciferase assay system according to the manufacturer’s
instructions (Promega Corp., Madison, WI, USA).
Relative light units from firefly luciferase activity were
measured using a luminometer (Mono Light 2010,
Analytical Luminescence Lab., San Diego, CA, USA).
To control for diﬀerences in transfection eﬃciency from
well to well, plasmid containing Renilla luciferase driven
by TK promotor was included in each transfection and
used for normalization.
Western blotting
Cells from the three experiments were lysed in lysis
buﬀer (150 mM NaCl, 50 mM Tris–HCl, pH 8·0, 1 mM
phenylmethylsulfonylfluoride and 1% Triton X-100)
with a sonicator, and total protein concentration was
measured by the method of Bradford (Bio-Rad). Thirty
micrograms protein were electrophoresed on a 10%
sodium dodecyl sulfate-polyacrylamide gel under
denaturing conditions. The proteins were transferred
onto a polyvinylidene difluoride (PVDF) membrane
(Immobilon-P, Millipore, Bedford, MA, USA) for
150 min at 250 mA. After the filter was blocked by
incubating the membranes with blocking solution (1
PBS, 0·15% Tween 20 and 5% non-fat milk) for 2 h at
room temperature, the membranes were hybridized with
each specific primary antibody overnight at 4 C.
Anti-rabbit polyclonal VEGF antibody (Santa Cruz
Biotechnology, Santa Cruz, CA, USA), polyclonal
antibody to p38 MAPK, phospho-specific p38 MAPK,
MAP kinase kinase 3/6 (MKK3/6), phospho-specific
MKK3/6, cAMP response element binding protein
(CREB), and phospho-specific CREB (New England
Biolabs, Inc., Beverly, MA, USA) diluted 1:1000 were
applied to the membrane. The filter was then washed
four times with phosphate buﬀered slaine Tween-20
(PBST), and incubated with horseradish peroxidase-
conjugated secondary antibody diluted 1:1000 for 60 min
at room temperature. The detection of specific signals
was performed using the ECL method (Amersham
Biosciences Corp., Piscataway, NJ, USA). Equal amounts
of protein loading were confirmed by Coomassie Blue
staining of the gel.
Enzyme-linked immunosorbent assay (ELISA)
The amount of VEGF protein secreted by podocytes in
culture medium was measured by commercially available
quantitative sandwich enzyme immunoassay (R&D
Systems, Minneapolis, MN, USA). The assay method was
designed to recognize both the 164 and 120 amino acid
residue forms of mouse VEGF. The sensitivity of ELISA
for VEGF was 3 pg/ml. The intra-assay coeﬃcient of
variation was 4·7% and the interassay coeﬃcient of
variation was 6·4%. For measurement of secreted soluble
VEGF in cultured medium, conditioned media were
collected at the end of the treatment periods. All particu-
lates were then removed by centrifugation at 4000 g
for 10 min and stored at –20 C before the measurement
of VEGF proteins. Supernatants were diluted five-fold
with diluent solution according to the manufacturer’s
instructions. Fifty microliters of sample with an equal
volume of diluent were dispensed in a 96-microwell
plate, precoated with polyclonal antibody specific for
mouse VEGF. The plates were incubated at room
temperature for 2 h, washed 5 times, and developed with
100 µl color reagent per well. The intensity of the color
was measured in an ELISA reader at 540 nm.
Electrophoretic mobility shift assay (EMSA)
Podocytes were treated with 100 nM angiotensin II for
8 h. Nuclear extracts were prepared by the method of
Dignam et al. (1983). Briefly, nuclear extracts (5 µg
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protein) were preincubated with poly(dl-dC)zpoly(dl-dC)
(2 µg), dithiothreitol (0·3 mM), and reaction buﬀer
(12 mM Tris, pH 7·9, 2 mM MgCl2, 60 mM KCl,
0·12 mM EDTA, and 12% glycerol) with or without
CREB antiserum (1–2 µl) for 30 min at 4 C. 32P-
Labeled oligonucleotide containing a consensus cAMP
response element (CRE) sequence (5-AGAGATTGCC
TGACGTCAGAGAGCTAG-3, Promega) was then
added, and the reaction mixtures were incubated for
10 min at 37 C. The reaction mixtures were then
separated on a 4% nondenaturing polyacrylamide gel at
200 V for 2 h. The gel was dried and autoradiographed.
Anti-CREB antibody (Santa Cruz Biotechnology) was
used for supershift. Unlabeled double-stranded oligonu-
cleotides with one copy of CRE or Oct1 (5-TGTCGAA
TGCAAATCACTAGAA-3, Promega) were used as
competitor.
Statistical analysis
We used non-parametric analysis due to the small
sample number. Results are expressed as means S.D.
Kruskall-Wallis was used for comparison of more than
two groups, followed by Mann–Whitney U test for
comparison, using a microcomputer-assisted program
with SPSS for Windows 10·0 (SPSS Inc., Chicago, IL,
USA). P<0·05 was considered statistically significant.
Results
Effects of Ang-II on VEGF mRNA and protein
production
When diﬀerent concentrations of Ang-II were added to
podocytes for 6 h, VEGF mRNA expression incremen-
tally increased in an Ang-II concentration-dependent
manner compared with controls (1 nM 0·430·01;
10 nM 0·950·10; 100 nM 1·950·07; control
0·280·04). For Ang-II concentrations of 1, 10 and
100 nM, VEGF mRNA levels were time-dependently
increased at 6 h and 24 h compared with that of the
control group (group with Ang-II at 100 nM: 6 h
1·950·07, 24 h 4·250·62, 72 h 1·320·09). As
shown in Fig. 1, the stimulatory eﬀect of Ang-II on
VEGF mRNA levels showed significant increases at 6 h
and 24 h, and decreased at 72 h, although its level was
still higher compared with the control group.
To define the role of angiotensin type 1 (AT1) and
type 2 (AT2) receptors involved in Ang-II-mediated
Figure 1 Effects of Ang-II and Ang-II type 1 receptor blockade
(losartan) on the expression of VEGF mRNA and the effect of
Ang-II on the transcriptional activity of VEGF in cultured
podocytes. (A) Representative RT-PCR showing the 207 bp
product, which is identical to the 260 to 266 nucleotide of
mouse alternatively spliced VEGF164. In addition, a second
279 bp product was also detected, but the density of the band
was much weaker than the 207 bp band. The 279 bp band had
an additional 72 nucleotides corresponding to the VEGF188
isoform. In this figure, only the major band of the RT-PCR
product is shown. Podocytes were exposed to different
concentrations of Ang-II with or without different concentrations
of losartan for 6, 24 and 72 h. (B) Densitometric analysis of
RT-PCR data. Results are expressed as an optical density ratio
of VEGF/-actin. Data are shown as means±S.D. of 3
independent experiments with triplicate dishes. (C) Podocytes
were co-transfected with VEGF promotor-driven luciferase
vector and TK-driven Renilla luciferase plasmid. Then cells
were treated with Ang-II at concentrations of 1, 10 or 100 nM
for 24 h. VEGF reporter activity was normalized to Renilla
luciferase activity. Data are shown as means±S.D. n=6 in each
group. Ang, angiotensin II; Los, losartan. *P,0·05,
**P,0·001 vs control. #P,0·05, ##P,0·01 vs group treated
with 100 nM Ang-II.
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VEGF mRNA upregulation, podocytes were preincu-
bated with losartan, a selective AT1 receptor antagonist
and PD123319, a selective AT2 receptor antagonist
under the influence of 100 nM Ang-II. Losartan at a
concentration of 1 µM did not show a significant eﬀect
on VEGF mRNA expression. However, supplementa-
tion with 10 and 100 µM losartan significantly inhibited
the VEGF mRNA expression induced by Ang-II (in the
group with 100 µM losartan: 6 h 0·980·14, 24 h
2·240·09, 72 h 0·560·04) (Fig. 1A,B).
Effect of Ang-II on transcriptional activity of VEGF in
cultured podocytes
Since Ang-II stimulated VEGF mRNA and protein
production, we wished to confirm using a luciferase
reporter assay whether VEGF production induced by
Ang-II actually increased its transcriptional activity.
Podocytes transfected with VEGF–luciferase exhibited
an increase in luciferase activity after stimulation with
Ang-II in a dose-dependent manner. Although Ang-II
treatment did not induce a significant increase in
transcriptional activity at a concentration of 1 and
10 nM, VEGF transcriptional activity was significantly
increased 2·5-fold at a concentration of 100 nM
compared with controls (Fig. 1C).
VEGF protein content in podocytes, evaluated by
western blot, also increased in a concentration- and
time-dependent manner after 6-h treatment with Ang-II
(Fig. 2A,B). Densitometric analysis of the VEGF protein
demonstrated a 1·9-fold (at 6 h), 2·5-fold (at 24 h) and
2·7-fold (at 72 h) higher level compared with controls in
the Ang-II (100 nM)-treated group. Losartan pretreat-
ment (100 µM) induced a reduction of 16% at 6 h, 44%
at 24 h, and 56% at 72 h in VEGF synthesis induced by
Ang-II (100 nM).
To confirm the eﬀect of Ang-II on the upregulation of
VEGF protein synthesis, the secretory types of VEGF
were measured by the ELISA technique. Ang-II
stimulation also increased the release of VEGF protein
in a dose- and time-dependent manner. The levels of
released VEGF after exposure for 6 h to 1 nM, 10 nM
and 100 nM Ang-II (17218 pg/105 cells/ml, 222
22 pg/105 cells/ml, and 34228 pg/105 cells/ml re-
spectively) were significantly higher than the control cells
(9411 pg/105 cells/ml) (Fig. 2C). For an Ang-II
concentration of 100 nM, the time course of VEGF
release showed 34228 pg/105 cells/ml at 6 h, 424
20 pg/105 cells/ml at 24 h, and 42618 pg/105 cells/
ml at 72 h compared with the level of controls (6 h
9411 pg/105 cells/ml, 24 h 10110 pg/105 cells/
ml, 72 h 11612 pg/105 cells/ml).
Supplementation of culture media with losartan even
at a concentration of 1 µM showed significant inhibition
of VEGF release. In comparison with the100 nM Ang-II
treatment group the levels of VEGF release in the group
with prior treatment with losartan (100 µM) were
significantly inhibited at 6 h (Ang-II 34228 pg/
105 cells/ml vs Ang-II+losartan 12311 pg/105 cells/
ml), 24 h (Ang-II 42420 pg/105 cells/ml vs Ang-II+
losartan 16511 pg/105 cells/ml), and 72 h (Ang-II
42618 pg/105 cells/ml vs Ang-II+losartan 124
11 pg/105 cells/ml) (Fig. 2C). However, PD123319,
Figure 2 Effect of Ang-II and Ang-II type 1 receptor blockade
(losartan) on VEGF protein in cultured podocytes. Podocytes
were exposed to different concentrations of Ang-II with or
without different concentrations of losartan for 6, 24 and 72 h.
(A) VEGF protein in podocytes was detected as a single band
of approximately 42 kDa. Thirty micrograms proteins were
electrophoresed on 10% sodium dodecyl sulfate-
polyacrylamide gel. (B) Densitometric data are shown as
means±S.D. of 3 independent experiments with triplicate
dishes. (C) Secretory VEGF levels from culture supernatants
were measured by ELISA. Data are shown as means±S.D. of
3 independent experiments with triplicate dishes.
Ang, angiotensin II; Los, losartan. *P,0·05, **P,0·01,
***P,0·001 vs control. #P,0·05, ##P,0·01 vs group treated
with 100 nM Ang-II.
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which is a selective AT2 receptor antagonist, did not
show any significant eﬀects on Ang-II-induced VEGF
mRNA expression and protein production (Fig. 3).
Effects of Ang-II on the activation of p38 MAPK
Since Ang-II stimulated VEGF mRNA and protein
production, we further evaluated whether VEGF
production induced by Ang-II depends on the p38
MAPK pathway. We first examined the activation of
p38 MAPK in response to Ang-II stimulation with
100 nM Ang-II, which was the concentration of Ang-II
that induced maximal production of VEGF synthesis.
The activation of p38 MAPK, assessed by measuring the
levels of phospho-specific p38 MAPK, was found to
increase rapidly in response to Ang-II after one hour.
The maximal activity was observed at the 6-h interval,
densitometric analysis showed a 3·4 times higher level
compared with controls (Fig. 4A). Following this peak,
the level of p38 MAPK phosphorylation gradually
decreased but remained higher than controls. However,
the total p38 MAPK protein level did not diﬀer among
the groups.
Figure 3 Effects of Ang-II type 2 receptor blockade
(PD123319) on the expression of VEGF mRNA and protein
secretion in cultured podocytes. Podocytes were exposed to
100 nM Ang-II with or without different concentrations of
PD123319 for 6, 24 and 72 h. (A) Densitometric analysis of
RT-PCR data. Results are expressed as an optical density ratio
of VEGF/-actin. Data are shown as means±S.D. of 3
independent experiments with triplicate dishes. (B) Secretory
VEGF proteins were measured in culture supernatant using
ELISA, which recognizes both the 164 and 120 amino acid
residue forms of mouse VEGF. Data are shown as means±S.D.
of 3 independent experiments with triplicate dishes.
Ang, angiotensin II. *P,0·05 vs group treated with 100 nM
Ang-II.
Figure 4 Effect of Ang-II on the activation of p38 MAPK protein
and MKK3/6 protein in cultured podocytes. Different
concentrations of Ang-II were added to the culture media at
final concentrations of 1 nM, 10 nM and 100 nM for 30 min. At
100 nM Ang-II, podocytes were harvested at 30 min, 1 h, 6 h,
and 24 h. (A) Representative Western blot of phospho-specific
p38 mitogen activated protein kinase (MAPK) protein in
cultured podocytes in response to Ang-II treatment at 30 min,
1 h, 6 h and 24 h. (B) Representative Western blot of
phospho-specific p38 mitogen activated protein kinase kinase
3/6 (MKK3/6) protein in cultured podocytes in response to
Ang-II treatment at 30 min, 1 h, 6 h and 24 h. Densitometric
data are shown as means±S.D. of 3 independent experiments
with triplicate dishes. *P,0·05 vs control.
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Effects of Ang-II on the activation of MKK3/6
We next examined the eﬀect of Ang-II on the activation
of MKK3/6, which is an upstream activator of p38
MAPK. Phospho-specific MKK3/6 levels, an indication
of MKK3/6 activation, peaked in response to Ang-II at
30 min and remained at higher levels throughout the
study period (1·8-fold on average) (Fig. 4B). The increase
in phospho-specific MKK3/6 levels occurred earlier
than that in phospho-specific p38 MAPK levels.
However, there was no significant diﬀerence in total
MKK3/6 protein expression among the groups.
Effects of Ang-II on the activation of CREB
To determine whether the activation of the p38 MAPK
pathway could induce a parallel increase in the activity
of a p38 MAPK target transcription factor, we observed
the activation of CREB, which is a known transcription
factor for the synthesis of VEGF (Shima et al. 1996).
CREB activation measured by the level of phosph-
specific CREB demonstrated dose- and time-dependent
increments after Ang-II stimulation. Maximum activity
was observed at 24 h incubation, and densitometric
analysis showed 2·5 times higher levels compared with
controls (Fig. 5). However, total CREB protein
expression was not changed according to the concen-
tration of Ang-II and the stimulation time.
Effects of p38 MAPK inhibitor (SB203580) on VEGF
protein and mRNA expression increased by Ang-II
stimulation
We next examined whether p38 MAPK is involved in
Ang-II-induced VEGF production since p38 MAPK,
MKK3/6 and CREB were activated by Ang-II
treatment. Thus, the inhibitory eﬀect of SB203580 on
Ang-II-induced VEGF synthesis was evaluated. With
increasing concentrations of SB203580, Ang-II-induced
VEGF mRNA expression significantly decreased, indi-
cating that SB203580 acts as an inhibitor of VEGF
synthesis. At a concentration of 10 µM SB203580,
VEGF mRNA expression was markedly suppressed
from 30 min in response to 100 nM Ang-II (30 min:
Ang-II 0·400·03 vs Ang-II+SB203580 0·170·05;
1 h: Ang-II 0·980·11 vs Ang-II+SB203580 0·33
0·06; 6 h: Ang-II 1·950·07 vs Ang-II+SB203580
0·460·02; 24 h: Ang-II 4·250·62 vs Ang-II+
SB203580 0·860·02) (Fig. 6).
With western blot analysis, VEGF protein synthesis
from podocytes also showed significant inhibition by
pre-treatment with SB203580 from 30 min. Densitomet-
ric analysis demonstrated that SB203580 treatment
Figure 5 Effect of Ang-II on the activation of CREB protein in
cultured podocytes. Different concentrations of Ang-II were
added to the culture media at final concentrations of 1 nM,
10 nM and 100 nM for 30 min. At 100 nM Ang-II, podocytes
were harvested at 30 min, 1 h, 6 h, and 24 h. Western blot was
performed using both total CREB antibody and
phospho-specific CREB antibody. Densitometric data are
shown as means±S.D. of 3 independent experiments with
triplicate dishes. *P,0·05 vs control.
Figure 6 Effects of p38 MAPK inhibitor (SB203580) on the
expression of VEGF mRNA induced by Ang-II in cultured
podocytes. (A) Representative RT-PCR product. Podocytes
were exposed to 100 nM Ang-II with or without different
concentrations of SB203580 for 30 min, 1 h, 6 h and 24 h.
(B) Densitometric analysis of RT-PCR data. Results are
expressed as an optical density ratio of VEGF/-actin. Data are
shown as means±S.D. of 3 independent experiments with
triplicate dishes. *P,0·05, **P,0·01 vs control. #P,0·05
between SB203580-treated groups. ##P,0·01 vs group
treated with 100 nM Ang-II.
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induced a reduction of 42% at 1 h, 66% at 6 h, and 54%
at 24 h in VEGF protein synthesis induced by Ang-II
(Fig. 7A).
To confirm the inhibitory eﬀect of SB203580 on
VEGF protein release, secretory types of VEGF were
measured by the ELISA technique. As illustrated in
Fig. 7B, SB203580 pretreatment prevented Ang-II-
induced VEGF release in a concentration-dependent
manner. Supplementation of culture media with
SB203580 even at a concentration of 1 µM showed
significant inhibition of VEGF release. The levels of
VEGF release in the group with prior treatment with
SB203580 (10 µM) were significantly inhibited at 1 h
(Ang-II 24413 pg/105 cells/ml vs Ang-II+SB203580
1149 pg/105 cells/ml), 6 h (Ang-II 34228 pg/
105 cells/ml vs Ang-II+SB203580 16311 pg/
105 cells/ml), and 24 h (Ang-II 42420 pg/105 cells/
ml vs Ang-II+SB203580 13411 pg/105 cells/ml).
Effect of Ang-II on electrophoretic mobility shift of
CRE elements
To confirm that Ang-II-induced phosphorylation of the
p38MAPK family proteins actually promotes the binding
aﬃnity of CREB, gel mobility-shift assays were per-
formed by using an oligonucleotide probe containing the
consensus sequence of CRE. When podocytes were
treated with 100 nM Ang-II, the CRE DNA–protein
complex formation, (the binding of nuclear protein to
CRE oligonucleotide containing consensus CRE (5-
TGACGTCA-3)), was increased in a time-dependent
manner (Fig. 8A). Ang-II-induced phosphorylation of
CREB was consistent with increased binding aﬃnity of
CREB (Fig. 8B). Anti-CREB antibody caused supershift,
indicating the presence of CREB protein within the CRE
DNA–protein complexes (Fig. 8C, lanes 1–4). 32P-
Labeled CRE oligonucleotide was incubated with
nuclear extracts in the presence of 0·2-, 2- and 20-fold
molar excess of unlabeled competitor. Ang-II-induced
protein binding to the 32P-labeled CRE probe was inhib-
ited by the unlabeled oligonucleotide containing the CRE
sequence but not that containing the Oct-1 sequence
(Fig. 8C, lanes 5–8). These findings suggest that angio-
tensin II enhances CRE-directed transcription of VEGF
gene through increasing the DNA binding activity and
phosphorylation of CREB.
Discussion
Among the many potential pathogenetic mechanisms
responsible for the development of diabetic kidney
disease, VEGF has been proposed to play a role in the
development of diabetic renal changes in type 1 and
type 2 diabetes (Duh & Aiello 1999). More direct
evidence of VEGF as a potential mediator of diabetic
nephropathy was gained from studies using VEGF
antibodies. Treatment with VEGF antibody was shown
to ameliorate both the classical early features of diabetic
renal disease, i.e. renal/glomerular hypertropy and
hyperfiltration and also, more importantly, late renal
changes (i.e. basement membrane thickening), with a
tendency to reduce total mesangial volume in type 1 and
2 experimental models (De Vriese et al. 2001, Flyvbjerg
et al. 2002).
Figure 7 Effects of p38 MAPK inhibitor (SB203580) on the
synthesis of VEGF protein in cultured podocytes. Podocytes
were exposed to 100 nM Ang-II with or without different
concentrations of SB203580 for 30 min, 1 h, 6 h, and 24 h. (A)
Representative western blot analysis showing the effect of p38
MAPK inhibitor (SB203580) on the cell content of VEGF
protein in cultured podocytes. Thirty micrograms proteins were
electrophoresed on 10% sodium dodecyl sulfate-
polyacrylamide gel. (B) Secretory VEGF proteins were
measured in culture supernatants using ELISA, which
recognizes both the 164 and 120 amino acid residue forms of
mouse VEGF. Densitometric data are shown as means±S.D. of
3 independent experiments with triplicate dishes. *P,0·05 vs
control. #P,0·05, ##P,0·01 vs group treated with 100 nM
Ang-II.
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We have previously demonstrated that expression of
VEGF increased in podocytes in diabetic patients in the
early phase of diabetic kidney disease, and that urinary
excretion of VEGF significantly increased according to
the degree of proteinurea in both human and diabetic
rats (Cha et al. 2000, 2004).
In the present study, VEGF mRNA expression
increased after exposure to Ang-II in a concentration-
dependent manner. This finding is similar to previous
studies in mesangial cells and vascular smooth muscle
cells in response to Ang-II (Williams et al. 1995, Kyriakis
& Avruch 2001). However, VEGF mRNA expression
peaked at 24 h and then gradually decreased.
That Ang-II causes an early, but not sustained, release
of VEGF in this study seems to argue against a role for
VEGF in diabetic nephropathy, but prolonged acti-
vation of renin-angiotensin systems in the diabetic state
in vivo may induce sustained VEGF overproduction for a
longer period.
The eﬀect of Ang-II on VEGF synthesis was maximal
at an Ang-II concentration of 100 nM. The concen-
tration of Ang-II required for the maximal eﬀects on
VEGF mRNA and protein secretion are consistent with
previous reports in vascular smooth muscle cells and
mesangial cells (Anderson et al. 1993, Williams et al.
1995). Similar to the findings with mRNA expression,
Figure 8 Effect of Ang-II on the binding affinity of CRE-binding protein. (A) Podocytes were treated with 100 nM Ang-II for 2 h, 4 h,
6 h, 8 h and 10 h. Nuclear extract was incubated with 32P-labeled oligonucleotide containing the consensus cAMP response
element (CRE) sequence, and the mixture was separated on a 4% nondenaturing polyacrylamide gel. (B) Podocytes were treated
with 100 nM Ang-II for 2 h, 4 h, 6 h, 8 h and 10 h. Nuclear protein was extracted and immunoblot was performed using
phospho-specific CREB antibody. (C) Podocytes were treated with 100 nM Ang-II for 8 h. The supershift assay was performed by
incubating nuclear extract with or without antibody against CREB. 32P-Labeled CRE oligonucleotide was incubated with nuclear
extracts in the presence of 0·2-, 2- and 20-fold molar excess of unlabeled competitor. The supershifted band is indicated by an
arrow (upper band).
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VEGF protein content in podocytes and VEGF release
also increased in a dose- and time-dependent manner. In
addition, we observed that VEGF transcriptional activity
also increased after stimulation with Ang-II in a
dose-dependent manner. This result is in line with
increased VEGF gene expression and protein produc-
tion after stimulation with Ang-II. Interestingly, the
stimulatory eﬀects of Ang-II on VEGF mRNA and
protein production were abolished not by pretreatment
with PD123319, which is an AT2 receptor antagonist,
but by pretreatment with losartan, which suggests that
the AT1 receptor is involved in Ang-II-mediated VEGF
synthesis.
P38 MAPK is a member of the MAPK family and
plays an essential role in regulating many cellular
processes, including inflammation, cell diﬀerentiation,
cell growth and death (Ono & Han 2000, Tian et al.
2000, Kyriakis & Avruch 2001). There are many reports
that Ang-II activates p38 MAPK in various kinds of cells
including mesangial cells (Reddy et al. 2002) and vascular
smooth muscle cells (Touyz et al. 2001). There is now a
wealth of data supporting a direct role for p38 MAPK as
a signaling pathway in the production of VEGF (Tanaka
et al. 2000, Jung et al. 2001, Duyndam et al. 2003,
Tokuda et al. 2003, Tsai et al. 2003). Therefore, in this
study, we focused on the p38 MAPK pathway to identify
the signaling pathways that mediate Ang-II-induced
VEGF synthesis.
Since Ang-II stimulated VEGF production in a
time-dependent manner with a peak level at the 24-h
interval, we examined whether Ang-II activates the p38
MAPK pathway up to 24 h. The activation of p38
MAPK occurred in response to Ang-II after 1 h, peaking
at 6 h, and then gradually decreased. Although p38
MAPK activation began to decline at 24 h, it was
maintained at a significant level. In addition, Ang-II
rapidly induced the activation of MKK3/6 and CREB.
Since the VEGF gene contains a CRE in its promoter
region, activation of CREB can induce the transcript for
VEGF (Shima et al. 1996). Braun et al. (2001) reported
that the hypoxia responsive element and CRE are
equally involved in the regulation of VEGF expression
in various tissues in diabetic rats.
In our experiments, activation of CREB also occurred
at 30 min of exposure, with the peak occurring at the
24-h interval following incubation. We also demon-
strated that Ang-II augmented CREB DNA binding
aﬃnity in podocytes associated with rapid phosphory-
lation of CREB. Taken together, these results suggest
that Ang-II activated the p38 MAPK pathway including
CREB phosphorylation in podocytes.
Finally, we also examined the possible role of p38
MAPK in Ang-II-induced VEGF production. Pretreat-
ment with the p38 MAPK inhibitor, SB203580, resulted
in a dose-dependent decrease in Ang-II-induced VEGF
mRNA transcription. SB203580 is widely used as a
potent inhibitor of p38 MAPK and its primary activity is
to inhibit p38 MAPK activity by binding to the ATP
acceptor pocket (Young et al. 1997). However, it has
recently been reported that SB203580 can also inhibit
the phosphatidylinositol 3-kinase/protein kinase B
pathway, cyclin G-associated kinase, and other apoptosis
regulatory protein kinases (Lali et al. 2000, Godl et al.
2003). Thus, our results suggest that Ang-II-induced
VEGF expression in podocytes is mediated, in part,
through the p38 MAPK pathway. Furthermore,
Ang-II-induced VEGF protein production was signifi-
cantly suppressed by SB203580, suggesting that an
Ang-II-p38 MAPK-VEGF pathway may exist and may
be active in podocytes.
Although we did not observe whether Ang-II could
increase VEGF production by podocytes in vivo, several
studies have suggested a close relationship between the
renin–angiotensin system (RAS) and VEGF in experi-
mental animal models of diabetes. Treatment with
Ang-II type 1 receptor antagonist attenuated renal struc-
tural injury and suppressed the VEGF expression in the
glomeruli in streptozotocin-induced diabetic rats (Qin
et al. 2003). In addition, angiotensin converting enzyme
inhibitor prevented diabetes-induced podocyte injuries
such as a decrease in podocyte number and foot process
broadening, which results in structural and functional
alterations in both type 1 and type 2 diabetic rats (Mifsud
et al. 2001, Gross et al. 2003). Thus, we can postulate that
Ang-II is involved in VEGF overexpression which
accompanies diabetic nephropathy, and our in vitro data
provide a potential mechanism for the beneficial eﬀect of
RAS blockade in diabetic nephropathy.
In conclusion, the present study provides evidence
that Ang-II stimulated VEGF synthesis in cultured
mouse podocytes, and that p38 MAPK activity
increased after stimulation with Ang-II in association
with both MKK3/6 and CREB activation. Further-
more, treatment with a potent p38 MAPK inhibitor
abolished Ang-II-mediated VEGF production. Taken
together, these results suggest that Ang-II-induced
VEGF production was mediated, in part, through the
p38 MAPK pathway in cultured mouse podocytes.
Acknowledgements
We thank Professor Peter Mundel and Sharon G Adler
for the generous gift of the mouse podocyte cell line. We
also thank Professor Patricia A D’Amore for the
generous gift of the mouse VEGF promotor-luciferase.
This work was supported, in part, by grant R01–2002–
000–00139–0 from the Basic Research Program of the
Korea Science and Engineering Foundation, and by the
Brain Korea 21 project in 2002. The authors declare
that there is no conflict of interest that would prejudice
the impartiality of this scientific work.
Y S KANG and others · Pathogenesis of diabetic nephropathy386
www.endocrinology-journals.orgJournal of Molecular Endocrinology (2006) 36, 377–388
References
Anderson PW, Yung SD & Willa AH 1993 Angiotensin II causes
mesangial cell hypertrophy. Hypertension 21 29–35.
Braun L, Kardon T, Reis-Porszasz ZS, Banhegyi G & Mandl J 2001
The regulation of the induction of vascular endothelial growth
factor at the onset of diabetes in spontaneously diabetic rats. Life
Science 69 2533–2542.
Brown LF, Berse B, Tognazzi K, Manseau EJ, Van de Water L,
Senger DR, Dvorak HF & Rosen S 1992 Vascular permeability
factor mRNA and protein expression in human kidney. Kidney
International 42 1457–1461.
Cha DR, Kim NH, Yoon JW, Jo SK, Cho WY, Kim HK & Won
NH 2000 Role of vascular endothelial growth factor in diabetic
nephropathy. Kidney International Supplement 58 S104–S112.
Cha DR, Kang YS, Han SY, Jee YH, Han KH, Han JY, Kim YS
& Kim NH 2004 Vascular endothelial growth factor is increased
during early stage of diabetic nephropathy in type II diabetic rats.
Journal of Endocrinology 183 183–194.
Clauss M, Gerlach M, Gerlach H, Brett J, Wang F, Familletti PC,
Pan YC, Olander JV, Connolly DT & Stern D 1990 Vascular
permeability factor: a tumor-derived polypeptide that induces
endothelial cells monocyte procoagulant activity, and promotes
monocyte migration. Journal of Experimental Medicine
172 1535–1545.
Cooper ME, Vranes D, Youssef S, Stacker SA, Cox AJ, Rizkalla B,
Casley DJ, Bach LA, Kelly DJ & Gilbert RE 1999 Increased renal
expression of vascular endothelial growth factor (VEGF) and its
receptor VEGFR-2 in experimental diabetes. Diabetes
48 2229–2239.
Craven PA & DeRubertis FR 1989 Protein kinase C is activated in
glomeruli from streptozotocin diabetic rats. Possible mediation by
glucose. Journal of Clinical Investigation 83 1667–1675.
De Vriese A, Tilton RG, Elger M, Stephan CC, Kritz W & Lameire
NH 2001 Antibody against vascular endothelial growth factor
improves early renal dysfunction in experimental diabetes. Journal
of the American Society of Nephrology 12 993–1000.
Dignam JD, Lebovitz RM & Roedr RG 1983 Accumate
transcription initiation by RNA polymerase II in a soluble extract
from isolated mammalian nuclei. Nucleic Acids Research
11 1475–1489.
Duh E & Aiello LP 1999 Vascular endothelial growth factor and
diabetes; the agonist versus antagonist paradox. Diabetes
48 1899–1906.
Duyndam MC, Hulscher ST, van der Wall E, Pinedo HM & Boven
E 2003 Evidence for a role of p38 kinase in hypoxia-inducible
factor-1-independent induction of vascular endothelial growth
factor expression by sodium arsenite. Journal of Biological Chemistry
278 6885–6895.
Ferrara N 1999 Role of vascular endothelial growth factor in
regulation of angiogenesis. Kidney International 56 794–814.
Flyvbjerg A, Dagnaes-Hansen F & De Vriese AS 2002 Amelioration
of long-term renal changes in obese type 2 diabetes mice by a
neutralizing vascular endothelial growth factor antibody. Diabetes
51 3090–3094.
Godl K, Wissing J, Kurtenbach A, Habenberger P, Blencke S,
Gutbrod H, Salassidis K, Stein-Gerlach M, Missio A & Daub H
2003 An eﬃcient proteomics method to identify the cellular
targets of protein kinase inhibitors. PNAS 100 15434–15439.
Gross ML, Ritz E, Schoof A, Helmke B, Parkman A, Tulp O,
Munter K & Amann K 2003 Renal damage in the SHR/N-cp
type 2 diabetes model: comparison of an angiotensin converting
enzyme inhibitor and endothelin receptor blocker. Laboratory
Investigation 83 1267–1277.
Gruden G, Thomas S, Burt D, Zhou W, Chusney G, Gnudi L &
Viberti G 1999 Interaction of angiotensin II and mechanical
stretch on vascular endothelial growth factor production by
human mesangial cells. Journal of the American Society of Nephrology
10 730–737.
Hoshi S, Nomoto K, Kuromitsu J, Tomari S & Nagata M 2002
High glucose induced VEGF expression via PKC and ERK in
glomerular podocytes. Biochemical and Biophysical Research
Communications 290 177–184.
Jung YD, Liu W, Reinmuth N, Ahmad SA, Fan F, Gallick GE &
Ellis LM 2001 Vascular endothelial growth factor is upregulated
by interleukin-1 beta in human vascular smooth muscle cells via
the p38 mitogen-activated protein kinase pathway. Angiogenesis
49 155–162.
Kang SW, Adler SG, LaPage J & Natarajan R 2001 p38
MAPK and MAPK kinase 3/6 mRNA and activities are
increased in early diabetic glomeruli. Kidney International
60 543–552.
Kim NH, Jung HH, Cha DR & Choi DS 2000 Expression of
vascular endothelial growth factor in response to high glucose in
rat mesangial cells. Journal of Endocrinology 165 617–624.
Kretzler M, Schroppel B, Merkle M, Huber S, Mundel P, Horster
M & Schlondorﬀ D 1998 Detection of multiple vascular
endothelial growth factor splice isoforms in single glomerular
podocytes. Kidney International Supplement 67 S159–S161.
Kyriakis JM & Avruch J 2001 Mammalian mitogen-activated protein
kinase signal transduction pathways activated by stress and
inflammation. Physiological Reviews 81 807–869.
Lali FV, Hunt AE, Turner SJ & Foxwell BMJ 2000 The pyridinyl
imidazole inhibitor SB203580 blocks phosphoinositide-dependent
protein kinase activity, protein kinase B phosphorylation, and
retinoblastoma hyperphosphorylation in interleukin-2 stimulated T
cells independently of p38 mitogen-activated protein kinase.
Journal of Biological Chemistry 275 7395–7402.
Leehey DJ, Singh AK, Alavi N & Singh R 2000 Role of angiotensin
II in diabetic nephropathy. Kidney International Supplement
58 S93–S98.
Mifsud SA, Allen TJ, Bertram JF, Hulthen UL, Kelly DJ, Cooper
ME, Wilkinson-Berka JL & Gilbert RE 2001 Podocyte foot
process broadening in experimental diabetic nephropathy:
amelioration with renin-angiotensin blockade. Diabetologia
44 878–882.
Mundel P, Reiser J, Zuniga Mejia Borja A, Pavenstadt H, Davidson
GR, Kriz W & Zeller R 1997 Rearrangements of the cytoskeleton
and cell contacts induce process formation during diﬀerentiation
of conditionally immortalized mouse podocyte cell lines.
Experimental Cell Research 236 248–258.
Ono K & Han J 2000 The p38 signal transduction pathway:
activation and function. Cellular Signalling 12 1–13.
Pupilli C, Lasagni L, Romagnani P, Bellini F, Mannelli M,
Misciglia N, Mavilia C, Vellei U, Villari D & Serio M 1999
Angiotensin II stimulates the synthesis and secretion of vascular
permeability factor/vascular endothelial growth factor in human
mesangial cells. Journal of the American Society of Nephrology
10 245–255.
Qin J, Zhang Z, Liu J, Sun L, Hu L, Cooper ME & Cao Z 2003
Eﬀects of the combination of an angiotensin II antagonist with an
HMG-CoA reductase inhibitor in experimental diabetes. Kidney
International 64 565–571.
Reddy MA, Adler SG, Kim YS, Lanting L, Rossi J, Kang SW,
Nadler JL, Shahed A & Natarajan R 2002 Interaction of MAPK
and 12-lipoxygenase pathway in growth and matrix protein
expression in mesangial cells. American Journal of Physiology Renal
Physiology 283 F985–F994.
Shima DT, Kuroki M, Deutsch U, Ng YS, Adamis AP & Amore
PAD 1996 The mouse gene for vascular endothelial growth
factor. Journal of Biological Chemistry 271 3877–3883.
Tanaka T, Kanai H, Sekiguchi K, Aihara Y, Yokoyama T, Arai M,
Kanda T, Nagai R & Kurabayashi M 2000 Induction of VEGF
gene transcription by IL-1 beta is mediated through
Pathogenesis of diabetic nephropathy · Y S KANG and others 387
www.endocrinology-journals.org Journal of Molecular Endocrinology (2006) 36, 377–388
stress-activated MAP kinases and Sp1 sites in cardiac myocytes.
Journal of Molecular and Cellular Cardiology 32 1955–1967.
Tian W, Zhang Z & Cohen DM 2000 MAPK signaling and
the kidney. American Journal of Physiology Renal Physiology
279 F593–F604.
Tokuda H, Hatakeyama D, Shibata T, Akamatsu S, Oiso Y &
Kozawa O 2003 p38 MAP kinase regulates BMP-4-stimulated
VEGF synthesis via p70 S6 kinase in osteoblasts. American
Journal of Physiology Endocrinology Metabolism 284 E1202–E1209.
Touyz RM, He G, El Mabrouk M, Diep Q, Mardigyan V &
Schiﬀrin EL 2001 Diﬀerential activation of extracellular
signal-regulated protein kinase 1/2 and p38 mitogen
activated-protein kinase by AT1 receptors in vascular smooth
muscle cells from Wistar-Kyoto rats and spontaneously
hypertensive rats. Journal of Hypertension 19 553–559.
Tsai PW, Shiah SG, Lin MT, Wu CW & Kuo ML 2003
Up-regulation of vascular endothelial growth factor C in breast
cancer cells by heregulin-beta1. A critical role of p38/nuclear
factor-kappa B signaling pathway. Journal of Biological Chemistry
278 5750–5759.
Williams B & Schrier RW 1993 Glucose-induced protein kinase C
activity regulates arachidonic acid release and eicosanoid
production by cultured glomerular mesangial cells. Journal of
Clinical Investigation 92 2889–2896.
Williams B, Quinn Baker A, Gallacher B & Lodwick D 1995
Angiotensin II increases vascular permeability factor gene
expression by human vascular smooth muscle cells. Hypertension
25 913–917.
Young PR, McLaughlin MM, Kumar S, Kassis S, Doyle ML,
McNulty D, Gallagher TF, Fisher S, McDonnell PC, Carr SA,
Huddleston MJ, Seibel G, Porter TG, Livi GP, Adams JL & Lee
JC 1997 Pyridinyl imidazole inhibitors of p38 mitogen-activated
protein kinase bind in the ATP site. Journal of Biological Chemistry
272 12116–12121.
Ziyadeh FN, Fumo P, Rodenberger CH, Kuncio GS & Neilson EG
1995 Role of protein kinase C and cyclic AMP/protein kinase A
in high glucose-stimulated transcriptional activation of collagen
alpha 1 (IV) in glomerular mesangial cells. Journal of Diabetes
Complications 9 255–261.
Received in final form 26 January 2006
Accepted 1 February 2006
Made available online as an Accepted Preprint 6 February 2006
Y S KANG and others · Pathogenesis of diabetic nephropathy388
www.endocrinology-journals.orgJournal of Molecular Endocrinology (2006) 36, 377–388
